The National Institutes of Health (NIH) is conducting an early-stage clinical trial to evaluate the safety and efficacy of two licensed seasonal influenza vaccines administered with or without novel adjuvants.
Kedrion Biopharma has created the free, easy-to-use KEDRAB Dose Calculator to help healthcare providers treat rabies exposures.
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
A revised product label for Octapharma USA’s Octaplas (pooled plasma [human] solvent/detergent treated solution for intravenous infusion) to treat critically ill pediatric patients who require replacement of multiple coagulation factors has been approved by the U.S. Food and Drug Administration (FDA).
A new study shows the HPV vaccine is far more effective than expected, with benefits extending beyond those who receive the vaccine.
A previously unknown autoimmune muscle disease involving sudden onset of debilitating muscle pain and weakness has been identified by researchers at Washington University School of Medicine in St. Louis, Mo.
A final rule that went into effect Nov. 4 strengthens the Centers for Medicare and Medicaid Services’ ability to stop fraud before it happens.
The Centers for Medicare and Medicaid Services (CMS) has finalized a rule to update and modernize the Programs of All-Inclusive Care for the Elderly (PACE) that reflects updates based upon best practices in caring for frail and elderly individuals.
The U.S. Food and Drug Administration (FDA) released guidelines on the studies companies need to conduct to show their biosimilar is interchangeable with a biologic.
The Centers for Medicare and Medicaid Services (CMS) published a final rule for calculating state Medicaid disproportionate share hospital (DSH) cuts in the amount of $4 billion in 2020 and $8 billion for each subsequent year through 2025.
The National Institutes of Health (NIH) has awarded $945 million to battle addiction and chronic pain.
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.
